Epigenetic dysregulation of enhancers in neurons is associated with Alzheimer’s disease pathology and cognitive symptoms

• Published in: Nature communications Vol. 10; no. 1; pp. 2246 - 14
• Main Authors: Li, Peipei, Marshall, Lee, Oh, Gabriel, Jakubowski, Jennifer L., Groot, Daniel, He, Yu, Wang, Ting, Petronis, Arturas, Labrie, Viviane
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 21.05.2019; Nature Publishing Group; Nature Portfolio
• Subjects: 45/22; 45/23; 45/91; 631/208/176/1988; 631/378/1689/1283; Activation; Aged; Aged, 80 and over; Aging; Alzheimer Disease - genetics; Alzheimer Disease - pathology; Alzheimer's disease; Amyloid; Amyloid Precursor Protein Secretases - genetics; Amyloid Precursor Protein Secretases - metabolism; Apoptosis; Aspartic Acid Endopeptidases - genetics; Aspartic Acid Endopeptidases - metabolism; Cell Adhesion Molecules - genetics; Cell cycle; Cognitive ability; Cognitive Dysfunction - genetics; Cognitive Dysfunction - pathology; Cohort Studies; CpG islands; CpG Islands - genetics; Deoxyribonucleic acid; Disease control; DNA; DNA Methylation; Enhancer Elements, Genetic; Enhancers; Epigenesis, Genetic; Epigenetics; Female; Gene mapping; Humanities and Social Sciences; Humans; Male; Mapping; Middle Aged; multidisciplinary; Neurofibrillary tangles; Neurons; Neurons - pathology; Pathology; Prefrontal cortex; Prefrontal Cortex - cytology; Prefrontal Cortex - pathology; Science; Science (multidisciplinary); Senile plaques; Signs and symptoms; Up-Regulation; β-Site APP-cleaving enzyme 1

Epigenetic control of enhancers alters neuronal functions and may be involved in Alzheimer’s disease (AD). Here, we identify enhancers in neurons contributing to AD by comprehensive fine-mapping of DNA methylation at enhancers, genome-wide. We examine 1.2 million CpG and CpH sites in enhancers in pr...